Joan Montero and colleagues in Boston suggest a new strategy for melanoma patients
IBEC researcher Joan Montero authors a paper in Nature Communications which uncovers a key adaptation that melanoma cancer cells use to evade current therapies. This finding might allow physicians to use better drug combinations to improve patient outcomes in the future.
Despite significant advances in cancer diagnosis and treatment, most targeted cancer therapies fail to achieve complete tumor regressions or durable remission. Understanding why these treatments are not always efficient has remained a main challenge for researchers and physicians. Now, Joan Montero from the IBEC and colleagues at Dana-Farber Cancer Institute/Harvard Medical School in USA report in Nature Communications a mechanism that uncovers why some therapies fail to treat melanoma.

Investigadors de l’Institut de Bioenginyeria de Catalunya (IBEC) han publicat un estudi a la revista Nature Communications que revela que la transferència d’electrons pot tenir lloc mentre la proteïna s’apropa a la seva proteïna complementaria, i no només quan aquestes ja hi estan unides, com es pensava fins ara.
Els grups Smart-Nano-Bio-Devices i Nanobioengineering de l’IBEC s’han unit per resoldre el problema del moviment aleatori de micro i nanomotors.